Skip to main content
. 2022 Aug 12;5(12):e202201479. doi: 10.26508/lsa.202201479

Figure S2. Humoral responses in MM patients according to treatment.

Figure S2.

(A, B) MM patients were sub-grouped according to their Daratumumab treatment to evaluate SARS-CoV-2–specific IgG antibody levels (Panel A) and neutralization capacity (Panel B). (C, D) In addition, MM patients were sub-grouped if they underwent autologous hematopoietic stem cell transplantation (auto-HSCT), to evaluate the impact in the SARS-CoV-2–specific IgG antibodies levels (Panel C) and neutralization capacity (Panel D). For all panels, median values are indicated and P-values were obtained from Mann–Whitney test for comparison between groups. For panels (B) and (D), dotted line indicates the 25th percentile of neutralization titer from CG.